drugset / Trial / NCT00005852
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
Phase 2
Terminated
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Bone marrow from donors may be able to treat patients with severe aplastic anemia and patients whose bodies have rejected previous bone marrow transplantation. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have severe aplastic anemia or whose bodies have rejected previous bone marrow transplant.
Timeline
- Start
- 1996-06
- Primary completion
- 2007-07
- Completion
- 2007-07
Outcome
Outcome not reported
Stopped (Enrollment): “low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Methylprednisolone | Other / unclassified | — | Intravenous |
| Subject | OKT3 | Monoclonal antibody | — | Intravenous |
| Background | Cyclosporine | Peptide | — | Oral |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |